VYNE - VYNE Therapeutics Inc.

QQQ $ 475.71 $ -0.26 (-0.05 %)

DIA $ 417.33 $ 2.44 (0.59 %)

SPY $ 562.48 $ 0.83 (0.15 %)

TLT $ 101.29 $ 0.92 (0.92 %)

GLD $ 238.61 $ -0.02 (-0.01 %)

Previous Close

$ 1.88

Open

Bid

$ 1.88 x 100

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 1.57 - $ 4.48

Volume

33,461

Average Volume

Market Cap

27.73M

Beta (5Y Monthly)

$ 0.92

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-14-2024	06-30-2024	10-Q
2	05-09-2024	03-31-2024	10-Q
3	03-01-2024	12-31-2023	10-K
4	11-13-2023	09-30-2023	10-Q
5	08-14-2023	06-30-2023	10-Q
6	05-11-2023	03-31-2023	10-Q
7	03-14-2023	12-31-2022	10-K
8	11-14-2022	09-30-2022	10-Q
9	08-12-2022	06-30-2022	10-Q
10	05-12-2022	03-31-2022	10-Q
11	03-17-2022	12-31-2021	10-K
12	11-10-2021	09-30-2021	10-Q
13	08-12-2021	06-30-2021	10-Q
14	05-06-2021	03-31-2021	10-Q
15	03-04-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-06-2020	06-30-2020	10-Q
18	05-11-2020	03-31-2020	10-Q
19	03-03-2020	12-31-2019	10-K
20	10-31-2019	09-30-2019	10-Q
21	08-01-2019	06-30-2019	10-Q
22	05-02-2019	03-31-2019	10-Q
23	02-28-2019	12-31-2018	10-K
24	11-07-2018	09-30-2018	10-Q
25	08-01-2018	06-30-2018	10-Q
26	05-09-2018	03-31-2018	10-Q
27	03-28-2018	12-31-2017	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Buy on VYNE...
09/12/2024 15:33:19

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

VYNE Therapeutics Announces Phase 1a SAD D...
09/12/2024 12:13:02

VYN202 was generally well tolerated with no drug-related adverse events Pharmacokinetic results demonstrated dose-dependent exp...

HC Wainwright & Co. Reiterates Buy on VYNE...
08/15/2024 09:57:30

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

VYNE Therapeutics Q2 2024 GAAP EPS $(0.22)...
08/14/2024 12:07:27

VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $...

VYNE Therapeutics Announces Composition Of...
07/16/2024 12:05:42

12-health-care-stocks-moving-in-thursdays-intraday-session

12 Health Care Stocks Moving In Thursday's...
06/20/2024 16:32:10

Analyst Scoreboard: 4 Ratings For VYNE The...
06/14/2024 13:01:32

HC Wainwright & Co. Reiterates Buy on VYNE...
06/14/2024 10:01:57

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

VYNE Therapeutics Doses First Volunteers I...
06/13/2024 13:04:50

HC Wainwright & Co. Reiterates Buy on VYNE...
06/05/2024 15:21:26

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

VYNE Therapeutics Doses First Subject In P...
06/05/2024 12:01:46

HC Wainwright & Co. Reiterates Buy on VYNE...
05/09/2024 15:27:59

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

VYNE Therapeutics Q1 EPS $(0.15) Beats $(0...
05/09/2024 13:06:19

VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0...

HC Wainwright & Co. Reiterates Buy on VYNE...
05/06/2024 14:45:06

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

12-health-care-stocks-moving-in-mondays-pre-market-session

12 Health Care Stocks Moving In Monday's P...
05/06/2024 12:06:38

VYNE Therapeutics Announces FDA Clearance ...
05/06/2024 12:04:29

VYNE Therapeutics Presents VYN201 At 2024 ...
05/01/2024 12:45:19

Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo

12-health-care-stocks-moving-in-fridays-after-market-session

12 Health Care Stocks Moving In Friday's A...
03/29/2024 20:30:47

HC Wainwright & Co. Reiterates Buy on VYNE...
02/29/2024 20:06:04

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

Recap: VYNE Therapeutics Q4 Earnings
02/29/2024 13:30:06